Zenas BioPharma, Inc. (ZBIO): who owns it and who trades it
As of Nov 16, 2026, ZBIO insiders reported 17 purchases worth $11.4M in the last 12 months. The largest buyer was Leon O Moulder Jr (CEO), with $5.8M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Zenas BioPharma
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ZBIO
146 funds and institutions reported ZBIO shares worth $1.6B at the end of Q2 2026, about 99% of the company. The largest holder is FMR LLC (Fidelity) with 15.1%.
Funds and institutions (13F) 99%Everyone else 1%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 9.51M | 15.06% | $241M | +5% |
| SR One Capital Management, LP | 5.04M | 7.98% | $128M | No change |
| NEA Management Company, LLC | 4.02M | 6.37% | $102M | No change |
| Enavate Sciences Gp, LLC | 3.92M | 6.21% | $99.5M | No change |
| Federated Hermes, Inc. | 3.12M | 4.94% | $79.1M | -0% |
| BlackRock, Inc. | 2.69M | 4.25% | $68.2M | +32% |
| Capital International Investors | 2.50M | 3.96% | $63.5M | +3% |
| Polar Capital Holdings Plc | 2.41M | 3.82% | $61.2M | -5% |
| Royalty Pharma Sub-Manager, LLC | 2.39M | 3.78% | $60.6M | – |
| Fairmount Funds Management LLC | 2.36M | 3.74% | $59.9M | No change |
| State Street Corp | 2.06M | 3.26% | $52.2M | +40% |
| Nvp Associates, LLC | 1.84M | 2.91% | $46.7M | No change |
| Wellington Management Group LLP | 1.59M | 2.52% | $40.5M | +28% |
| Vanguard Capital Management LLC | 1.35M | 2.15% | $34.4M | +9% |
| Bank of America Corp | 1.23M | 1.95% | $31.2M | +217% |
| T. Rowe Price Associates | 1.23M | 1.94% | $31.1M | +243% |
| Alliancebernstein L.P. | 1.10M | 1.75% | $21.6M | +23% |
| Geode Capital Management, LLC | 882,654 | 1.40% | $22.4M | +35% |
| Two Sigma Investments, LP | 815,150 | 1.29% | $20.7M | +196% |
| EcoR1 Capital, LLC | 789,500 | 1.25% | $20M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ZBIO insiders reported $11.4M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Leon O Moulder Jr | CEO | Purchase | 60,000 | $16.88 | $1M | Form 4 |
| Apr 29, 2026 | Leon O Moulder Jr | CEO | Purchase | 35,000 | $17.62 | $617K | Form 4 |
| Apr 28, 2026 | Leon O Moulder Jr | CEO | Purchase | 25,000 | $18.02 | $450K | Form 4 |
| Mar 31, 2026 | Hongbo Lu | Director | Purchase | 3,768 | $18.63 | $70.2K | Form 4 |
| Mar 31, 2026 | Tomas Kiselak +3 | Director | Purchase | 150,000 | $20.00 | $3M | Form 4 |
| Mar 31, 2026 | Leon O Moulder Jr | CEO | Purchase | 34,000 | $19.31 | $657K | Form 4 |
| Mar 31, 2026 | Hongbo Lu | Director | Purchase | 75,000 | $20.00 | $1.5M | Form 4 |
| Mar 30, 2026 | Leon O Moulder Jr | CEO | Purchase | 20,000 | $18.23 | $365K | Form 4 |
| Feb 13, 2026 | Patricia L Allen | Director | Purchase | 4,160 | $26.36 | $110K | Form 4 |
| Feb 12, 2026 | Patricia L Allen | Director | Purchase | 5,700 | $24.34 | $139K | Form 4 |
| Feb 12, 2026 | Patricia L Allen | Director | Purchase | 5,000 | $23.77 | $119K | Form 4 |
| Feb 12, 2026 | Patricia L Allen | Director | Purchase | 5,000 | $26.50 | $132K | Form 4 |
| Feb 11, 2026 | Hongbo Lu | Director | Purchase | 25,985 | $22.50 | $585K | Form 4 |
| Feb 2, 2026 | Leon O Moulder Jr | CEO | Purchase | 57,000 | $17.96 | $1M | Form 4 |
| Jan 9, 2026 | Leon O Moulder Jr | CEO | Purchase | 20,000 | $16.55 | $331K | Form 4 |
| Jan 8, 2026 | Leon O Moulder Jr | CEO | Purchase | 30,000 | $16.30 | $489K | Form 4 |
| Jan 7, 2026 | Leon O Moulder Jr | CEO | Purchase | 50,000 | $16.38 | $819K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Leon O Moulder Jr | Chief Executive Officer, Director | $5.8M | – | May 18, 2026 |
| Tomas Kiselak | Director | $3M | – | Mar 31, 2026 |
| Hongbo Lu | Director | $2.2M | – | Mar 31, 2026 |
| Patricia L Allen | Director | $500K | – | Feb 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ZBIO short interest
High short interest. 16.7% of ZBIO shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 6%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 11.35M ZBIO shares were sold short, 16.7% of the shares outstanding, down 9.4% from the report before. At the average daily volume of 471,475 shares, buying them all back would take about 24.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 11.35M | 16.74% | -9% | 471,475 | 24.1 |
| Oct 15, 2026 | 12.54M | 19.24% | +5% | 666,058 | 18.8 |
| Sep 30, 2026 | 11.94M | 18.32% | +1% | 771,653 | 15.5 |
| Sep 15, 2026 | 11.87M | 18.21% | +1% | 529,251 | 22.4 |
| Aug 31, 2026 | 11.70M | 17.95% | +0% | 825,023 | 14.2 |
| Aug 14, 2026 | 11.66M | 17.89% | -1% | 553,670 | 21.1 |
| Jul 31, 2026 | 11.75M | 18.03% | -3% | 850,076 | 13.8 |
| Jul 15, 2026 | 12.17M | 19.28% | -0% | 976,880 | 12.5 |
| Jun 30, 2026 | 12.20M | 19.32% | +10% | 1.26M | 9.6 |
| Jun 15, 2026 | 11.13M | 17.63% | +2% | 575,802 | 19.3 |
| May 29, 2026 | 10.88M | 17.23% | +2% | 599,922 | 18.1 |
| May 15, 2026 | 10.69M | 16.93% | -2% | 501,405 | 21.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Zenas BioPharma company events
Zenas BioPharma filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026AnnouncementAs previously disclosed, on October 8, 2025, Zenas BioPharma, Inc. entered into a Sales Agreement with Jefferies LLC, with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value… Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 13, 2026AnnouncementShared information with investors. Filing
- Aug 13, 2026LeadershipAppointment of Christy J. Oliger Upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors, on August 12, 2026, the Board appointed Christy J. Oliger to serve on the Board as a Class II director to hold office until the Company’s annual meeting… Filing
- May 13, 2026LeadershipZenas BioPharma, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- Mar 31, 2026AgreementZenas BioPharma, Inc. completed its public offering of $200 million of its 2.50% Convertible Senior Notes due 2032. Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Feb 13, 2026LeadershipThe Board of Directors of Zenas BioPharma, Inc. approved the Company’s Amended and Restated Short-Term Incentive Plan, effective as of January 1, 2026. Filing
- Jan 5, 2026AnnouncementThe Company announced positive results from the INDIGO trial. Filing
- Dec 15, 2025LeadershipThe Board approved the Zenas BioPharma, Inc. 2026 Inducement Plan, the form of Non-Statutory Stock Option Agreement under the 2026 Inducement Plan, the form of Global Non-Statutory Stock Option Agreement under the 2026 Inducement Plan, the form of Restricted Stock Unit Agreement under the 2026… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Zenas BioPharma financials
Famous investors that hold ZBIO
3 of the 50 well-known investors we track reported holding ZBIO in their latest 13F filing. The largest position is Israel Englander's, worth $5.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 194,052 | $5.2M | 0.0% | -71% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 98,787 | $2.7M | 0.0% | +512% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 16,907 | $456K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ZBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 12.4% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G/A | 12.4% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
Questions about Zenas BioPharma, Inc. (ZBIO) stock
Who owns the most ZBIO stock?
The largest reported owner of Zenas BioPharma, Inc. (ZBIO) is FMR LLC (Fidelity), with 15.1% of the company. In total, 146 funds and institutions reported holding ZBIO at the end of Q2 2026, together about 99% of the shares. See the largest owners.
Are ZBIO insiders buying or selling?
In the last 12 months, ZBIO insiders reported 17 open-market purchases worth $11.4M and no sales. The latest trade was on May 18, 2026. See every trade.
What is the short interest in ZBIO?
As of Oct 30, 2026, 11.35M ZBIO shares were sold short, 16.7% of the shares outstanding, down 9.4% from the report before. At the average daily volume of 471,475 shares, buying them all back would take about 24.1 trading days (days to cover). See the history.
Which famous investors hold ZBIO?
3 of the 50 well-known investors we track reported ZBIO in their latest 13F filing, including Israel Englander, Steve Cohen, Paul Tudor Jones. The largest position is worth $5.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.